Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesEW -0.21%97 EV-to-EBITDA is 29.26 as of Jul. 23, 2026, which is 3% below its 10-year median of 30.04. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 78.63% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Edwards Lifesciences's enterprise value is $45,612 Mil.
Edwards Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,559 Mil. Therefore, Edwards Lifesciences's EV-to-EBITDA for today is 29.26.
The historical rank and industry rank for Edwards Lifesciences's EV-to-EBITDA or its related term are showing as below:
EW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 20.83 Med: 30.04 Max: 60.81
Current: 29.26
During the past 13 years, the highest EV-to-EBITDA of Edwards Lifesciences was 60.81. The lowest was 20.83. And the median was 30.04.
EW's EV-to-EBITDA is ranked worse than 78.63% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.08
vs EW: 29.26
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Edwards Lifesciences's PE Ratio (TTM) for today is calculated as:
Edwards Lifesciences's share price for today is $84.37.
Edwards Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Edwards Lifesciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's EV-to-EBITDA falls into.
Edwards Lifesciences's current Enterprise Value is $45,612 Mil.
Edwards Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,559 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a EV-to-EBITDA of 29.26 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Edwards Lifesciences. This is near median its historical median of 30.04. Over the past decade, Edwards Lifesciences' EV-to-EBITDA has ranged from 20.83 to 60.81. According to the industry distribution chart, Edwards Lifesciences ranks #401 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 78.6%.
Is Edwards Lifesciences' EV-to-EBITDA too high?
Edwards Lifesciences' current EV-to-EBITDA of 29.26 is near median its 10-year median of 30.04. Over the past 10 years, this metric has ranged from a low of 20.83 to a high of 60.81. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.08. Edwards Lifesciences' value of 29.26 is 107.8% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #401 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EV-to-EBITDA compare to BSX and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #401 out of 510 companies for EV-to-EBITDA. This places Edwards Lifesciences in the lower half of its industry. The industry median EV-to-EBITDA is 14.08. Edwards Lifesciences' value of 29.26 is 107.8% above this benchmark. Historically, Edwards Lifesciences' own EV-to-EBITDA has ranged from 20.83 to 60.81 over the past decade. While the company's 10-year median is 30.04 vs. the industry median of 14.08, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.08, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current EV-to-EBITDA of 29.26 is 107.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Edwards Lifesciences. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current EV-to-EBITDA is 29.26, which is near median its own 10-year median of 30.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Modestly Undervalued. The stock's GF Value™ is $93.87, compared to a current price of $84.37 — trading 10.1% below its estimated fair value. The current EV-to-EBITDA is 29.26, which is near median its 10-year median of 30.04 and 107.8% above the Medical Devices & Instruments industry median of 14.08. Edwards Lifesciences' overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current EV-to-EBITDA is 29.26 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $84.37 is trading 10.1% below its estimated GF Value™ of $93.87.
GuruFocus considers Edwards Lifesciences to be Modestly Undervalued.
Key valuation signals for EW:
EV-to-EBITDA: 29.26 (near median its 10-year median of 30.04)
GF Value™: $93.87 vs. price of $84.37 (10.1% below fair value)
Industry Position: 107.8% above the Medical Devices & Instruments median (#401 of 510)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
